Loading
Ceribell, Inc. Stock: price and insider trades · United States
Ceribell, Inc.: what insiders have been doing
Ceribell, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 21 insiders have disclosed 130 filings since 18 October 2025.
The flow runs one way only: 51 sales worth €8.0M, from 10 insiders, and no purchase. No amount is published for 6 filings, which the totals therefore leave out. At €840k, the sale published on 4 September 2026 by Chao Xingjuan is the largest of the period (0.11% of market cap).
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,812 companies, median 19 filings), a count of 130 filings is above the norm. Our records for Ceribell, Inc. go back to 2024, with no purchases and 58 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 89.1 m USD and net income at -53.4 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
170
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€8M
58 ops. · all time
Who traded when
BuySaleXingjuan Chao21 sales
David Foehr9 sales
Raymond Woo9 sales
Scott Blumberg7 sales
Parvizi Josef5 sales
Robertson Rebecca B5 sales
+4 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Ceribell, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$28.57.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,113 of 24,161 companies
28.3
score / 100
Value22
Quality35
FCF yld-4.3%
Earn yld-5.6%
EV/EBITDA·
ROE-44%
Gross mgn88%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$26.37
Analyst consensus
7 analystsStrong buy
US$24.00Target US$28.57(+8%)US$33.00
Income statement
RevenueUS$89.1M
Gross profitUS$78.3M88% margin
EBITDA-US$50.2M-56% margin
Net income-US$53.4M-64.7% margin
Valuation
PER (forward)-16.3x
P/Book7.9x
Beta0.93
Balance sheet & cash
Market capUS$1B
Total debtUS$22.3M
Free Cash Flow-US$41.6M
Debt / Equity17%
Profitability & ownership
ROE-43.9%
ROA-23.4%
% insiders11.8%
% institutions90.3%
Last declaration on 2 October 2026
Declarations170 total
4,864 shares@ US$3.650.0019% mcap1.9% of flowCommon StockSEC:0001193125-26-412606:0
23 shares@ US$4.700.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-412606:1
4,887 shares@ US$24.380.012% mcap13.0% of flowCommonSEC144:0001959173-26-007171
846 shares@ US$9.410.0009% mcap0.4% of flowCommon StockSEC:0001193125-26-394789:0
846 shares@ US$25.000.0023% mcap1.0% of flowCommon StockSEC:0001193125-26-394789:1
20,846 shares@ US$25.030.057% mcap5.1% of flowCommon StockSEC:0001193125-26-394799:0
846 shares@ US$25.0010.0023% mcap1.0% of flowCommonSEC144:0001959173-26-006985
20,846 shares@ US$25.02990.057% mcap5.1% of flowCommonSEC144:0001959173-26-006983
8,389 shares@ US$2.240.0020% mcap2.3% of flowCommon StockSEC:0001193125-26-388295:0
4,864 shares@ US$3.650.0019% mcap2.2% of flowCommon StockSEC:0001193125-26-388295:1
23 shares@ US$4.700.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-388295:2
1,755 shares@ US$24.260.0046% mcap6.4% of flowCommon StockSEC:0001193125-26-388299:0
7,500 shares@ US$4.700.0038% mcap5.3% of flowCommon StockSEC:0001193125-26-388299:1
7,500 shares@ US$24.250.020% mcap27.3% of flowCommon StockSEC:0001193125-26-388299:2
4,887 shares@ US$24.330.013% mcap14.5% of flowCommonSEC144:0001959173-26-006771
9,255 shares@ US$24.330.024% mcap33.8% of flowCommonSEC144:0001959173-26-006785
23,554 shares@ US$4.700.012% mcap1.1% of flowCommon StockSEC:0001193125-26-383893:1
39,540 shares@ US$24.610.11% mcap9.5% of flowCommon StockSEC:0001193125-26-383893:2
1,446 shares@ US$4.700.0007% mcap0.1% of flowCommon StockSEC:0001193125-26-383893:0
652 shares@ US$9.410.0007% mcap0.3% of flowCommon StockSEC:0001193125-26-383891:0
652 shares@ US$25.000.0018% mcap0.7% of flowCommon StockSEC:0001193125-26-383891:1
1,521 shares@ US$24.020.0039% mcap1.6% of flowCommon StockSEC:0001193125-26-365550:0
6,068 shares@ US$24.020.016% mcap1.4% of flowCommon StockSEC:0001193125-26-365546:0
1,979 shares@ US$24.020.0051% mcap5.8% of flowCommon StockSEC:0001193125-26-365552:0
993 shares@ US$24.020.0026% mcap3.6% of flowCommon StockSEC:0001193125-26-365554:0
25 of 170 declarations
About Ceribell, Inc.
Ceribell, Inc. is a US-listed medical technology company traded on the Nasdaq in the United States under the ticker CBLL. The company focuses on acute neurology, with a product platform designed to improve the diagnosis and management of patients with serious neurological conditions, especially seizure detection in hospital settings. Ceribell was founded in 2014 as Brain Stethoscope, Inc., changed its name to CeriBell, Inc. in 2015, and is headquartered in Sunnyvale, California. The business began commercial sales in 2018 after obtaining key FDA 510(k) clearances for its core hardware and software platform.
At the center of the franchise is the Ceribell System, a rapid-deployment EEG solution intended for bedside use in acute care. The portfolio includes disposable or wearable headbands, a recorder, a cloud-enabled portal, and the Clarity algorithm, which supports seizure detection and signal interpretation. Ceribell is increasingly positioning itself as a platform company rather than a single-product vendor. Recent development work has broadened the addressable market to include neonatal and pediatric patients, while new applications are being pursued in delirium monitoring and large-vessel occlusion (LVO) stroke detection. The company therefore combines product revenue with subscription/software revenue, which is strategically important for long-term margin expansion and recurring cash flows.
Read moreShow less
From a competitive standpoint, Ceribell occupies a specialized niche in a market where speed, ease of deployment, and clinical usability matter more than broad general-purpose features. Its differentiation lies in an integrated system that can be deployed across a range of hospital environments, from major academic centers to community hospitals. According to the latest annual report, the Ceribell System had been adopted by more than 600 hospitals as of year-end 2025, indicating meaningful commercial traction but still plenty of room for broader penetration.
Recent news has been favorable on both the commercial and regulatory fronts. Ceribell reported full-year 2025 revenue of $89.1 million, followed by first-quarter 2026 revenue of $26.5 million, up 29% year over year, with 680 active accounts at the end of the quarter. The company also announced FDA milestones including clearance for neonatal use of Clarity, FDA clearance for a delirium monitoring solution, and Breakthrough Device Designation for its LVO stroke detection and monitoring program. Management also highlighted supportive CMS reimbursement developments related to the delirium solution, which could further improve adoption economics if finalized. For international investors, Ceribell stands out as a high-growth, specialty medtech name on the Nasdaq in the United States, with a compelling innovation-led story, but one that remains dependent on clinical adoption, reimbursement pathways, and continued regulatory execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
